Results 31 to 40 of about 13,254 (218)

P-1184. Efficacy and Safety of Imipenem/Cilastatin/Relebactam (IMI/REL) in Treating Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia: A Systematic Literature Review of Randomized Control Trials [PDF]

Open Forum Infect Dis
Carolyn A. Cameron, Shalini Bagga, Vaneet Pal Kaur Khurana, Prashant Soni, Sachin Kumar, Emre Yücel   +5 more
europepmc   +3 more sources

Identification of Antibiotics in Surface-Groundwater. A Tool towards the Ecopharmacovigilance Approach: A Portuguese Case-Study

Antibiotics, 2021
Environmental monitoring, particularly of water, is crucial to screen and preselect potential hazardous substances for policy guidance and risk minimisation strategies. In Portugal, extensive data are missing.
Paula Viana, Leonor Meisel, Ana Lopes, Rosário de Jesus, Georgina Sarmento, Sofia Duarte, Bruno Sepodes, Ana Fernandes, Margarida M. Correia dos Santos, Anabela Almeida, M. Conceição Oliveira   +10 more
doaj   +1 more source

Wasp venom-induced acute kidney injury: current progress and prospects

Renal Failure, 2023
Wasp venom can trigger local and systemic reactions, with the kidneys being commonly affected, potentially causing acute kidney injury (AKI). Despite of the recent advances, our knowledge on the underlying mechanisms of toxicity and targeted therapies ...
Fanglin Yu, Ling Wang, Hai Yuan, Zhao Gao, Li He, Fengqi Hu   +5 more
doaj   +1 more source

Organic anion transporters also mediate the drug–drug interaction between imipenem and cilastatin

Asian Journal of Pharmaceutical Sciences, 2020
This study aimed to clarify that organic anion transporters (OATs) mediate the drug–drug interaction (DDI) between imipenem and cilastatin. After co-administration with imipenem, the plasma concentrations and the plasma concentration-time curve (AUC) of ...
Yanna Zhu, Xiaokui Huo, Changyuan Wang, Qiang Meng, Zhihao Liu, Huijun Sun, Aiping Tan, Xiaodong Ma, Jinyong Peng, Kexin Liu   +9 more
doaj   +1 more source

Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections: A Meta-analysis

Infection & Chemotherapy, 2021
Background Antimicrobial resistance is on the rise. The use of redundant and inappropriate antibiotics is contributing to recurrent infections and resistance.
Syeda Sahra, Abdullah Jahangir, Rachelle Hamadi, Ahmad Jahangir, Allison Glaser   +4 more
openalex   +2 more sources

Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance

JAC-Antimicrobial Resistance, 2023
Objectives To assess the relationship between renal function and efficacy/safety of imipenem/cilastatin/relebactam for the treatment of hospital-acquired/ventilator-associated pneumonia (HABP/VABP) from RESTORE-IMI 2 and determine the PTA. Methods Adults
J. Roberts, D. Nicolau, I. Martín-Loeches, C. DeRyke, M. Losada, Jiejun Du, Munjal Patel, M. Rizk, Amanda Paschke, L. Chen   +9 more
semanticscholar   +1 more source

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections

Drugs, 2021
Imipenem/cilastatin/relebactam (Recarbrio™) is an intravenously administered combination of the carbapenem imipenem, the renal dehydropeptidase-I inhibitor cilastatin, and the novel β-lactamase inhibitor relebactam.
Young-A. Heo
semanticscholar   +1 more source

Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram‐Negative Bacterial Infections: A Phase 1b, Open‐Label, Single‐Dose Clinical Trial

Journal of clinical pharmacology, 2023
Imipenem/cilastatin/relebactam is approved for the treatment of serious gram‐negative bacterial infections in adults. This study assessed the pharmacokinetics (PK), safety, and tolerability of a single dose of imipenem/cilastatin/relebactam (with a fixed
John S. Bradley, Nataliia Makieieva, Camilla Tøndel, Emmanuel Roilides, Matthew S Kelly, Munjal Patel, Pavan Vaddady, A. Maniar, Ying Zhang, Amanda Paschke, L. Chen   +10 more
semanticscholar   +1 more source

Dual drug delivery of vancomycin and imipenem/cilastatin by coaxial nanofibers for treatment of diabetic foot ulcer infections.

Materials Science and Engineering C: Materials for Biological Applications, 2021
Diabetic foot ulcer infections are the main causes of hospitalization in diabetics. The present study aimed to develop vancomycin and imipenem/cilastatin loaded core-shell nanofibers to facilitate the treatment of diabetic foot ulcers.
Farideh Davani, Mohsen Alishahi, M. Sabzi, M. Khorram, A. Arastehfar, K. Zomorodian   +5 more
semanticscholar   +1 more source

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Clinical Infectious Diseases, 2020
Background Imipenem combined with the β-lactamase inhibitor relebactam has broad antibacterial activity, including against carbapenem-resistant gram-negative pathogens.
Ivan Titov, R. Wunderink, A. Roquilly, Daniel Rodríguez Gonzalez, A. David-Wang, H. Boucher, K. Kaye, M. Losada, Jiejun Du, R. Tipping, M. Rizk, Munjal Patel, M. Brown, K. Young, N. Kartsonis, J. Butterton, Amanda Paschke, L. Chen   +17 more
semanticscholar   +1 more source